Lung cancer immunosuppression and therapeutic targeting of myeloid- derived suppressor cells

Abstract

Myeloid derived suppressor cells or MDSC are immune cells derived from the common myeloid progenitor which is able to develop erythrocytes , platelets or other granulocytes .They are separated into two different subsets ; PMN-MDSC and M-MDSC . MDSCs inhibit the immune system and are involved in tumor maintenance and development. It also impede therapies that use immunotherapy or other non-immune methods to cure cancer. MDSCs were first identified as suppressors of T cells, namely CD8+ T-cell responses. The fact that MDSCs have a high number of immunosuppressive mechanisms does not imply that all of them are active at the same time. The type of MDSCs that multiplied in response to sickness, as well as the stage of the disease and the site of suppression, all influence the frequency of a particular immunosuppressive mechanism. MDSCs will most likely adopt a dominant suppressive mechanism at any one time, which will change as the disease advances. As a result, evaluating the significance of MDSCs in cancer should entail an examination of their functional activity as well as one or two chemicals produced by these cells. It also implies that targeting a single mechanism for therapeutic reasons may be ineffective unless that mechanism has been determined to be prevalent in the type of cancer being treated.